{"denoms":[{"counts":[{"groupId":"BG000","value":"504"},{"groupId":"BG001","value":"506"},{"groupId":"BG002","value":"1010"}],"units":"Participants"}],"groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"BG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"BG001","title":"Panitumumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.2","value":"60.2"},{"groupId":"BG001","spread":"10.9","value":"59.6"},{"groupId":"BG002","spread":"11.1","value":"59.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"183"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"370"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"321"},{"groupId":"BG001","value":"319"},{"groupId":"BG002","value":"640"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"455"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Japanese"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"530"}]}],"title":"White or Caucasian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"316"}]}],"title":"North America, Western Europe and Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"348"},{"groupId":"BG002","value":"694"}]}],"title":"Rest of World"}],"description":"Stratification factor. Rest of world includes South America, Asia and South Africa","paramType":"NUMBER","title":"Geographic region","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"320"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"309"},{"groupId":"BG002","value":"608"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"82"}]}],"title":"Grade 2"}],"description":"0 = Fully active, able to carry on all pre-disease performance without restriction.\n\n1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, ie, light housework or office work.\n2. = Ambulatory and capable of all self-care but unable to carry out any work. activities. Up and about \\> 50% of waking hours.\n3. = Capable of only limited self-care, confined to a bed or chair \\> 50% of waking hours.\n4. = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.\n5. = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) performance status","unitOfMeasure":"participants"}]}